Clinical Trial Update: Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

View source ↗

Summary

A terminated clinical trial update investigates whether genetic markers can predict response to paclitaxel in patients with newly diagnosed stage III/IV ovarian…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Ovarian Cancer, Peritoneal Cavity Cancer | Status: TERMINATED